U.S., Sept. 24 -- ClinicalTrials.gov registry received information related to the study (NCT07187375) titled 'Pharmacokinetics, Safety and Tolerability of Crinecerfont in Participants With Congenital Adrenal Hyperplasia Who Are Less Than 2 Years Old' on Sept. 18.
Brief Summary: The main objective for this study is to evaluate the pharmacokinetics (PK) of crinecerfont in pediatric participants 0 to <2 years of age with congenital adrenal hyperplasia (CAH).
Study Start Date: Sept. 28
Study Type: INTERVENTIONAL
Condition:
Congenital Adrenal Hyperplasia
Intervention:
DRUG: Crinecerfont
Oral solution
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Neurocrine Biosciences
Published by HT Digital Content Services with permission from Hea...